NASDAQ:ELVN Enliven Therapeutics (ELVN) Stock Price, News & Analysis $52.95 +0.14 (+0.27%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$52.93 -0.02 (-0.04%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Enliven Therapeutics Stock (NASDAQ:ELVN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Enliven Therapeutics alerts:Sign Up Key Stats Today's Range$51.74▼$53.7150-Day Range$33.63▼$54.3352-Week Range$14.78▼$54.88Volume368,655 shsAverage Volume1.18 million shsMarket Capitalization$3.22 billionP/E RatioN/ADividend YieldN/APrice Target$70.50Consensus RatingModerate Buy Company Overview Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors. The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications. Enliven applies structure-guided drug design and advanced screening technologies to optimize potency, selectivity and oral bioavailability of its lead compounds. Preclinical studies have demonstrated proof-of-concept in multiple tumor models, supporting planned clinical investigations aimed at overcoming resistance mechanisms that limit the efficacy of conventional therapies. Headquartered in the greater Boston area, Enliven Therapeutics operates in a hub of biopharmaceutical innovation and maintains strategic collaborations with academic institutions and contract research organizations. The company’s management team brings together seasoned executives and scientists with extensive experience in oncology drug discovery and clinical development. Through its focused R&D strategy, Enliven seeks to advance novel precision therapies that address critical unmet needs in cancer treatment. AI Generated. May Contain Errors. Read More Enliven Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreELVN MarketRank™: Enliven Therapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 352nd out of 836 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingEnliven Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialEnliven Therapeutics has a consensus price target of $70.50, representing about 33.1% upside from its current price of $52.95.Amount of Analyst CoverageEnliven Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Enliven Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Enliven Therapeutics are expected to decrease in the coming year, from ($1.57) to ($1.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enliven Therapeutics is -31.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enliven Therapeutics is -31.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnliven Therapeutics has a P/B Ratio of 6.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Enliven Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.64% of the float of Enliven Therapeutics has been sold short.Short Interest Ratio / Days to CoverEnliven Therapeutics has a short interest ratio ("days to cover") of 9.41.Change versus previous monthShort interest in Enliven Therapeutics has recently increased by 1.46%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEnliven Therapeutics does not currently pay a dividend.Dividend GrowthEnliven Therapeutics does not have a long track record of dividend growth. News and Social Media3.9 / 5News Sentiment1.27 News SentimentEnliven Therapeutics has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Enliven Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for ELVN on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat Follows2 people have added Enliven Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Enliven Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,113,888.00 in company stock.Percentage Held by Insiders3.00% of the stock of Enliven Therapeutics is held by insiders.Percentage Held by Institutions95.08% of the stock of Enliven Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Enliven Therapeutics' insider trading history. Receive ELVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enliven Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ELVN Stock News HeadlinesAnalysts Set Enliven Therapeutics, Inc. (NASDAQ:ELVN) Target Price at $69.172 hours ago | americanbankingnews.comEnliven Therapeutics (NASDAQ:ELVN) Hits New 52-Week High After Analyst UpgradeJuly 23 at 1:52 AM | americanbankingnews.comUniversal basic income is not impossible. It exist (kind of)Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income Plan - direct ownership in 14 entities controlling U.S. pipelines, terminals, and processing plants, targeting 10% annually. The plan issues 42 payouts per year and is on pace to distribute $53 billion in 2025 - a record. The next distribution drops in days. | Freedom Financial (Ad)The Goldman Sachs Group Boosts Enliven Therapeutics (NASDAQ:ELVN) Price Target to $67.00July 23 at 1:18 AM | americanbankingnews.comProfitable biotechs strut their stuff as stock market stumblesJuly 17, 2026 | msn.comLori Anne Kunkel Sells 10,000 Shares of Enliven Therapeutics (NASDAQ:ELVN) StockJuly 9, 2026 | insidertrades.comStocks to watch: 14 names test and tease new buy zonesJuly 8, 2026 | msn.comEnliven Therapeutics (ELVN) Stock Looks Overvalued As Returns Surge But Book Value LagsJuly 4, 2026 | finance.yahoo.comSee More Headlines ELVN Stock Analysis - Frequently Asked Questions How have ELVN shares performed this year? Enliven Therapeutics' stock was trading at $15.40 at the beginning of 2026. Since then, ELVN stock has increased by 243.8% and is now trading at $52.95. How were Enliven Therapeutics' earnings last quarter? Enliven Therapeutics, Inc. (NASDAQ:ELVN) posted its quarterly earnings data on Thursday, May, 7th. The company reported ($0.38) EPS for the quarter, beating analysts' consensus estimates of ($0.44) by $0.06. When did Enliven Therapeutics IPO? Enliven Therapeutics (ELVN) raised $80 million in an initial public offering (IPO) on Thursday, March 12th 2020. The company issued 4,700,000 shares at $16.00-$18.00 per share. Who are Enliven Therapeutics' major shareholders? Enliven Therapeutics' top institutional investors include Assenagon Asset Management S.A. (0.50%), Tema ETFs LLC (0.10%), Handelsbanken Fonder AB (0.03%) and FNY Investment Advisers LLC. Insiders that own company stock include Samuel Kintz, 5Am Partners Vi, Llc, Joseph P Lyssikatos, Rishi Gupta, Anish Patel, Benjamin Hohl, Lori Anne Kunkel, Richard A Heyman and Rahul D Ballal. View institutional ownership trends. How do I buy shares of Enliven Therapeutics? Shares of ELVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Enliven Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enliven Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Broadcom (AVGO), Tesla (TSLA) and Palo Alto Networks (PANW). Company Calendar Last Earnings5/07/2026Today7/25/2026Next Earnings (Estimated)8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 ELVN's financial health is in the Green zone, according to TradeSmith. ELVN has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ELVN CIK1672619 Webimaratx.com Phone617-927-9989FaxN/AEmployees50Year Founded2019Price Target and Rating Average Price Target for Enliven Therapeutics$70.50 High Price Target$80.00 Low Price Target$62.00 Potential Upside/Downside+33.1%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$103.69 million Net MarginsN/A Pretax MarginN/A Return on Equity-21.04% Return on Assets-20.41% Debt Debt-to-Equity RatioN/A Current Ratio40.32 Quick Ratio40.32 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.74 per share Price / Book6.84Miscellaneous Outstanding Shares60,900,000Free Float59,078,000Market Cap$3.22 billion OptionableOptionable Beta0.24 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:ELVN) was last updated on 7/26/2026 by MarketBeat.com Staff. From Our PartnersThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredOxford Club Analyst’s Urgent AI WarningAlexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThe 90%-off options that empty accountsA call that cost $3.00 last month now trades for $0.30 - a 90% discount that looks tempting. It's not a bar...Profits Run | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe Weekly Options Trick Wall Street Doesn't AdvertiseThe most profitable trading desks don't guess market direction, they collect income regardless of it. A 25-yea...Base Camp Trading | SponsoredHave you seen Elon’s new “supercurrency”? (It affects you)Elon Musk just became the world's first trillionaire following the biggest IPO in history, giving him access t...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
